DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

Recurrent lung cancer patients benefit from proton therapy: study

by John W. Mitchell , Senior Correspondent
A five-year retrospective study of patients with reoccurring lung cancer and other thoracic tumors concluded that, contrary to common protocol, intensity-modulated proton therapy (IMPT) increased life expectancy with few serious side effects.

Study details were presented Friday at the Multidisciplinary Thoracic Cancers Symposium held in San Francisco.

Story Continues Below Advertisement

Dunlee announces the relaunch of DA135 CT/e, DA165NP and Akron tubes

Dunlee announces the return of the DA135 CT/e, DA165NP, S532B and S532Q(known as the Akron tubes) CT Replacement tubes, making its full portfolio of CT tubes for GE and Siemens CT scanners available once again.Click to learn more



"We've been using this technique at our cancer center for a few years. We believed the therapy was serving patients pretty well," Dr. Jennifer Ho, lead author and a resident in radiation oncology at the University of Texas MD Andersen Cancer Center in Houston, told HCB News. "This retrospective evidence supports the treatment."

The research team conducted a look-back at the medical records of 27 patients who received re-irradiation for thoracic tumors using the IMPT technique through prospective clinical trials at a single institution between 2011 and 2016. All patients had previously received curative thoracic radiotherapy.

They found that the follow-up median re-irradiation occurred at about 30 months. This yielded an average survival rate of 18 months. At one year, the majority of patients were free from local and regional relapse, and about half of patients were free from relapse after a year.

The study found that the higher the dose, the lower the reoccurrence or progression of the cancer.

Side effects were low as well, according to Ho. Only two of the 27 patients experienced moderate to severe long-term lung toxicity. No severe long-term esophageal side effects nor life-threatening toxicity were noted.

"Our median survival rate of 18 months is the highest I've seen in any studies. I believe the best rates achieved prior were 10 to 14 months," said Ho. "Patient selection is certainly a big factor."

She explained that physicians have to be selective in choosing patients they believe can tolerate the extra treatments. She also said that patients need about 30 months to recover from their initial radiotherapy treatment to have the stamina to be successful with the follow-up IMPT therapy.

Conventionally, patients for whom lung cancer has returned are offered pain and palliative care options, rather than continued treatment.

Lung cancer causes more deaths in the U.S. than any other cancer because it is aggressive and recurrence is common. Many patients are not candidates for surgery, and curative radiation therapy often damages surrounding organs.

"We are really excited going forward, and look forward to refining the treatment to help more patients," said Ho.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED